The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 352:843 February 24, 2005 Number 8
NextNext

APL during Gefitinib Treatment for Non–Small-Cell Lung Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: Gefitinib is an orally active inhibitor of tyrosine kinase epidermal growth factor,1 with clinical effectiveness in the control of non–small-cell lung cancer. We describe 3 patients with possible treatment-related acute promyelocytic leukemia (APL) among 108 consecutive patients with advanced, recurrent non–small-cell lung cancer who were treated with gefitinib between November 2001 and December 2004 at our institution (Table 1). Other than these three patients, no patients with other cancers have been identified in this cohort.

View this table:
[in this window]
[in a new window]
  		Table 1. Characteristics of Three Patients with APL during Treatment with Gefitinib for Recurrence of Non–Small-Cell Lung Cancer.

 
Chemotherapy, including the use . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.